Brind.
  1. Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.
  2. Eli Lilly and Novo Nordisk faced market pressure from federal policy, while the CalRx program funded Civica for production runs.

Walgreens is serving as a distribution point for the state's CalRx insulin glargine program, while Civica handles the manufacturing of the biosimilar insulin.

1 report, 1 independent Updated Aug 18
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Walgreens is serving as a distribution point for the state's CalRx insulin glargine program, while Civica handles the manufacturing of the biosimilar insulin.

Who's involved

What this event is mainly about
WalgreensCivica

Keep exploring

Part of

Eli Lilly and Novo Nordisk faced market pressure from federal policy, while the CalRx program funded Civica for production runs. All 1 developments

Within Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.

The entities involved

Coverage

Newest first; wire copies grouped